Hypnion's HY10275 meets insomnia endpoint

Hypnion (Lexington, Mass.) said oral HY10275 met the primary endpoint of a reduction in wake after sleep onset (WASO) in a Phase II trial to treat insomnia. In the double-blind, French trial in 52 pat...